The antibiotic resistance arrow of time: Efflux pump induction is a general first step in the evolution of mycobacterial drug resistance

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4806-4815

  Schmalstieg, Aurelia M ^a   Srivastava, Shashikant ^a   Belkaya, Serkan ^a   Deshpande, Devyani ^a   Meek, Claudia ^b   Leff, Richard ^b   Van Oers, Nicolai S C ^a   Gumbo, Tawanda ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AZITHROMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CHROMOSOME MUTATION; CONTROLLED STUDY; EVOLUTION; HYPOTHESIS; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM MARINUM; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM ULCERANS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; AZITHROMYCIN; CONSERVED SEQUENCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM AVIUM; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT; TIME FACTORS;

EID: 84865445025     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05546-11     Document Type: Article

References (50)

1. Ainsa JA, et al. 1998. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J. Bacteriol. 180:5836-5843. (Pubitemid 28514198)
2. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans. Automated Control 19:716-723.
3. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. (Pubitemid 44968990)
4. Benson CA, et al. 2003. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin. Infect. Dis. 37:1234-1243. (Pubitemid 37372514)
5. Blaser J, Stone BB, Zinner SH. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl A):131-137. (Pubitemid 15079557)
6. Canetti G, et al. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. World Health Organ. 29:565-578.
7. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
8. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
9. Del Grosso M, et al. 2002. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J. Clin. Microbiol. 40:774-778. (Pubitemid 34208622)
10. Del Grosso GM, Scotto DA, Iannelli F, Pozzi G, Pantosti A. 2004. Tn2009, a Tn916-like element containing mef(E) in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48:2037-2042. (Pubitemid 38691594)
11. Deshpande D, Gumbo T. 2011. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. Future Microbiol. 6:433-439.
12. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. 2010. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob. Agents Chemother. 54:1728-1733.
13. Deshpande D, et al. 2010. Moxifloxacin Pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob. Agents Chemother. 54:2534-2539.
14. Drusano GL. 2005. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25:150S-158S. (Pubitemid 41790090)
15. Dunne M, et al. 2000. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin. Infect. Dis. 31:1245-1252. (Pubitemid 32295457)
16. Eum SY, et al. 2010. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122-128.
17. Fernandez-Moreno MA, Carbo L, Cuesta T, Vallin C, Malpartida F. 1998. A silent ABC transporter isolated from Streptomyces rochei F20 induces multidrug resistance. J. Bacteriol. 180:4017-4023. (Pubitemid 28373501)
18. Gay K, Stephens DS. 2001. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J. Infect. Dis. 184:56-65. (Pubitemid 32568501)
19. Gillespie SH. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46:267-274. (Pubitemid 34087167)
20. Gordin FM, et al. 1999. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 28:1080-1085. (Pubitemid 29203542)
21. Gumbo T. 2010. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy, p 1549-1570. In Brunton LL, Chabner B, Knollmann B (ed), Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed. McGraw Hill Medical, New York, NY.
22. Gumbo T, et al. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651. (Pubitemid 39411014)
23. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. 2009. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
24. Haas S, Scully B, Cohen D, Radhakrishnan J. 2005. Mycobacterium avium complex infection in kidney transplant patients. Transpl. Infect. Dis. 7:75-79. (Pubitemid 41337795)
25. Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M. 2005. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J. Clin. Microbiol. 43:4407-4412. (Pubitemid 41298220)
26. Jumbe NL, et al. 2006. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:310-317. (Pubitemid 43042937)
27. Kaplan JE, et al. 2009. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58:1-207.
28. Lee L-F, Chen CW. 1998. Multidrug resistant genes in Streptomyces. Actinomycetologica 12:148-152.
29. Liu P, et al. 2007. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob. Agents Chemother. 51:103-109. (Pubitemid 46047694)
30. Louie A, et al. 2007. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:3988-4000. (Pubitemid 350057798)
31. Louw GE, et al. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276.
32. Louw GE, et al. 2009. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob. Agents Chemother. 53:3181-3189.
33. Luke DR, Foulds G, Cohen SF, Levy B. 1996. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob. Agents Chemother. 40:2577-2581. (Pubitemid 26367647)
34. McMurry L, Petrucci RE, Jr, Levy SB. 1980. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 77:3974-3977. (Pubitemid 10022532)
35. Meier A, et al. 1996. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174:354-360. (Pubitemid 26251422)
36. Meier A, et al. 1994. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob. Agents Chemother. 38:381-384. (Pubitemid 24054270)
37. Mitchison DA. 1998. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 2:10-15. (Pubitemid 28108937)
38. Naser SA, Ghobrial G, Romero C, Valentine JF. 2004. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 364:1039-1044. (Pubitemid 39248662)
39. Nash KA. 2001. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob. Agents Chemother. 45:1607-1614. (Pubitemid 32466324)
40. Nash KA, Inderlied CB. 1995. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. 39:2625-2630.
41. Pasipanodya JG, Gumbo T. 2011. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr. Opin. Pharmacol. 11:457-463.
42. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of anti-tuberculosis therapy. Clin. Infect. Dis. 55:169-177.
43. Ramon-Garcia S, Martin C, Ainsa JA, De RE. 2006. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J. Antimicrob. Chemother. 57:252-259. (Pubitemid 43160166)
44. Santagati M, Iannelli F, Oggioni MR, Stefani S, Pozzi G. 2000. Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2585-2587. (Pubitemid 30650926)
45. Srivastava S, et al. 2010. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201:1225-1231.
46. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 204:1951-1959.
47. Torriani FJ, Behling CA, McCutchan JA, Haubrich RH, Havlir DV. 1996. Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J. Infect. Dis. 173:942-949. (Pubitemid 26001171)
48. Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. 1994. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J. Infect. Dis. 170:1601-1605. (Pubitemid 24369927)
49. Vecchione JJ, Alexander B, Jr, Sello JK. 2009. Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor. Antimicrob. Agents Chemother. 53:4673-4677.
50. Zhang T, Bishai WR, Grosset JH, Nuermberger EL. 2010. Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob. Agents Chemother. 54:2806-2813.